

Medivir's CFO Magnus Christensen to leave the company

Stockholm — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today that its CFO, Magnus Christensen, has decided to leave his position to assume a corresponding role at Cinclus Pharma. Magnus has served as Medivir's CFO since 2019 and also held the position of interim CEO from May 2021 to January 2022.

The recruitment process to appoint a new CFO has been initiated. Magnus Christensen will remain in his current role during a transition period to ensure a structured and orderly transition.

"I would like to extend my sincere thanks to Magnus for his dedicated commitment and significant contributions to the development of the company. It has been a true pleasure working with him," says Medivir's CEO, Jens Lindberg.

For additional information, please contact;

Jens Lindberg
Chief Executive Officer
Medivir AB
M: +46 72 531 11 17
Email: jens.lindberg@medivir.com

Magnus Christensen
Chief Financial Officer
Medivir AB
M: +46 73 125 06 20
Email: Magnus.Christensen@medivir.com

About Medivir

Medivir develops innovative drugs with a focus on cancer where the unmet medical needs are high. The drug candidates are directed toward indication areas where available therapies are limited or missing and there are great opportunities to offer significant improvements to patients. Medivir is focusing on the development of fostroxacitabine bralpamide (fostrox), a drug candidate designed to selectively treat cancer cells in the liver and to minimize side effects. Collaborations and partnerships are important parts of Medivir's business model, and the drug development is conducted either by Medivir or in partnership. Medivir's share (ticker: MVIR) is listed on Nasdaq Stockholm's Small Cap list. www.medivir.com.

This information is information that Medivir is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-12-08 07:30 CET.